Background: The selective co-stimulation modulator abatacept demonstrated efficacy for
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …

Background Some children with juvenile idiopathic arthritis either do not respond, or are
intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour …

Objectives This phase III study evaluated the efficacy and safety of rituximab plus
methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate …

Abstract Purpose of Review The present paper establishes a narrative and analytical review
of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus …

Objective To assess the effects of the B lymphocyte stimulator (BLyS)–specific inhibitor
belimumab on immunologic biomarkers, including B cell and T cell populations, and …

Regulatory T cells have an important role in the control of self-reactivity, and in the
pathogenesis of autoimmune inflammatory conditions. The aim of this work was to perform a …

Systemic lupus erythematosus is the diffuse autoimmune connective tissue disease that
most frequently involves pulmonary involvement, affecting 20% of 90% of the patients. The …

Objective We previously documented that abatacept was effective and safe in patients with
juvenile idiopathic arthritis (JIA) who had not previously achieved a satisfactory clinical …

Aim: To identify periodontal bacterial DNA (PBDNA) by PCR in subgingival dental plaque
(SDP), serum and synovial fluid (SF) of rheumatoid arthritis (RA) with periodontal disease …

We studied the clinical and immunological effects of Rituximab (anti-CD20) therapy in
patients with lupus nephritis. In an open clinical trial, 22 patients with active systemic lupus …